Soft Tissue Sarcoma

The final diagnosis was established through liver biopsy and immunohistochemical analysis. The patient is currently undergoing treatment with a multidrug chemotherapy regimen.

P2, N=135, Recruiting, Centre Oscar Lambret | Not yet recruiting --> Recruiting

P=N/A, N=33, Recruiting, Mayo Clinic | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028

After transient benefit from first-line doxorubicin plus ifosfamide chemotherapy, the disease progressed despite second-line PD-1 inhibitor combined with anlotinib. Treatment was subsequently switched to cadonilimab, a PD-1/CTLA-4 bispecific antibody, in combination therapy, resulting in a progression-free survival of more than 24 months. This outcome appears encouraging compared with previously reported CCS benchmarks; however, given the single-case nature and combined treatment strategy, the specific contribution of cadonilimab should be interpreted with caution.

Together, our results show that controlled epigenetic activation of STING in STS enhances immune infiltration and tumor cell killing. Targeting STING through CRISPR activation may therefore represent a promising therapeutic strategy for STS.

This case highlights the complexity of diagnosing SS, given its subtle clinical findings, slow growth, and atypical presentation. Multidisciplinary care is essential for optimizing diagnosis and treatment outcomes. Prompt recognition and comprehensive care can improve patients' prognosis.

Subcutaneous ESOS is rare and diagnostically challenging. This case highlights the importance of imaging, histopathology, immunohistochemistry, and multidisciplinary management, particularly in resource-limited settings.

No definitive conclusions can be drawn regarding the relationship between 18F-FMISO uptake and hypoxia biomarker expression. Larger, adequately powered prospective studies are essential to validate these findings, clarify potential correlations, and determine the clinical utility of 18F-FMISO PET/CT as a noninvasive hypoxia biomarker in STS.

P2, N=73, Recruiting, Northwestern University | N=29 --> 73 | Trial completion date: Jul 2029 --> Jul 2033

These findings support the investigation of rational combination approaches informed by sensitive detection methods and functional testing to address resistance in ultra-rare cancers. Implications: Integrative multi-omic profiling combined with functional testing in DSRCT reveals patient-specific vulnerabilities and biologically targetable receptor and DNA damage response dependencies, while defining immune states that may inform therapeutic response and rational combination strategies in this rare, fusion-driven cancer.

Here, we describe two patients with EWSR1::PATZ1 sarcoma, of which one patient was initially misdiagnosed as synovial sarcoma and RMS on two occasions. These patients underscore the diagnostic challenges and therapeutic uncertainties surrounding EWSR1::PATZ1 fusion sarcomas, emphasizing the need for further large collaborative studies to establish optimal prognostic implications and management strategies for this rare entity.

These findings highlight the clinical relevance of immune infiltration in retroperitoneal DDLPS and LMS. Moreover, they support the rationale for further exploration of the immune architecture for prognostic biomarkers and development of targeted immunotherapeutic strategies to improve the clinical outcomes of the patients.